Roche said it plans to start a Phase 2 study evaluating a combination of two investigational obesity drugs—petrelintide and enicepatide—during the year. The company positioned the pairing as a potential path to improved safety and efficacy, aiming to differentiate from a crowded GLP-1-centered obesity market. The strategy reflects how obesity developers are moving beyond single-agent approaches toward combinations intended to deliver stronger weight outcomes or better tolerability. Roche’s plan also signals continued investment in long-acting peptide and incretin-adjacent mechanisms. Sponsors and CRO partners will watch how Roche designs the trial—especially dose schedules, endpoints for weight and metabolic markers, and how it handles background therapies—given how directly investors will compare outcomes against leading programs from other large biopharmas.